HOXC6 in the prognosis of prostate cancer

References

• Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079–1092.
   PubMed Web of Science ®Google Scholar
• Soares N. d C P, Teodoro AJ, Oliveira FL, et al. Influence of lycopene on cell viability, cell cycle, and apoptosis of human prostate cancer and benign hyperplastic cells. Nutr Cancer. 2013;65:1076–1085.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
   PubMed Web of Science ®Google Scholar
• Keane FK, Chen MH, Zhang D, et al. The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. Cancer. 2014;120:1787–1793.
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
   PubMed Web of Science ®Google Scholar
• Reiter RJ, Tan DX, Manchester LC, et al. A walnut-enriched diet reduces the growth of LNCaP human prostate cancer xenografts in nude mice. Cancer Invest. 2013;31:365–373.
   PubMed Web of Science ®Google Scholar
• Kong HY, Byun J. Screening and characterization of a novel RNA aptamer that specifically binds to human prostatic acid phosphatase and human prostate cancer cells. Mol Cells. 2015;38:171–179.
   PubMed Web of Science ®Google Scholar
• Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Chao C, Chi M, Preciado M, et al. Methylation markers for prostate cancer prognosis: a systematic review. Cancer Causes Control. 2013;24:1615–1641.
   PubMed Web of Science ®Google Scholar
• Daniunaite K, Jarmalaite S, Kalinauskaite N, et al. Prognostic value of RASSF1 promoter methylation in prostate cancer. J Urol. 2014;192:1849–1855.
   PubMed Web of Science ®Google Scholar
• Lin YL, Xie PG, Wang L, et al. Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy. Med Sci Monit. 2014;20:1376–1382.
   PubMed Web of Science ®Google Scholar
• Huang L, Pu Y, Hepps D, et al. Posterior Hox gene expression and differential androgen regulation in the developing and adult rat prostate lobes. Endocrinology 2007;148:1235–1245.
   PubMed Web of Science ®Google Scholar
• Klein D, Benchellal M, Kleff V, et al. Hox genes are involved in vascular wall-resident multipotent stem cell differentiation into smooth muscle cells. Sci Rep. 2013;3:2178.
   PubMed Web of Science ®Google Scholar
• Hussain I, Bhan A, Ansari KI, et al. Bisphenol-A induces expression of HOXC6, an estrogen-regulated homeobox-containing gene associated with breast cancer. Biochim Biophys Acta. 2015;1849:697–708.
   PubMed Web of Science ®Google Scholar
• Bodey B, Bodey B, Jr., Siegel SE, et al. Immunocytochemical detection of the homeobox B3, B4, and C6 gene products in breast carcinomas. Anticancer Res. 2000;20:3281–3286.
   PubMed Web of Science ®Google Scholar
• Ansari KI, Hussain I, Shrestha B, et al. HOXC6 Is transcriptionally regulated via coordination of MLL histone methylase and estrogen receptor in an estrogen environment. J Mol Biol. 2011;411:334–349.
   PubMed Web of Science ®Google Scholar
• Moon SM, Kim SA, Yoon JH, et al. HOXC6 is deregulated in human head and neck squamous cell carcinoma and modulates Bcl-2 expression. J Biol Chem. 2012;287:35678–35688.
   PubMed Web of Science ®Google Scholar
• Fujiki K, Duerr EM, Kikuchi H, et al. Hoxc6 is overexpressed in gastrointestinal carcinoids and interacts with JunD to regulate tumor growth. Gastroenterology. 2008;135:907–916.
   PubMed Web of Science ®Google Scholar
• Bodey B, Bodey B, Jr,., Siegel SE, et al. Homeobox B3, B4, and C6 gene product expression in osteosarcomas as detected by immunocytochemistry. Anticancer Res. 2000;20:2717–2721.
   PubMed Web of Science ®Google Scholar
• Bijl J, van Oostveen JW, Kreike M, et al. Expression of HOXC4, HOXC5, and HOXC6 in human lymphoid cell lines, leukemias, and benign and malignant lymphoid tissue. Blood. 1996;87:1737–1745.
   PubMed Web of Science ®Google Scholar
• Hamid AR, Hoogland AM, Smit F, et al. The role of HOXC6 in prostate cancer development. Prostate. 2015;75:1868–1876.
   PubMed Web of Science ®Google Scholar
• Ramachandran S, Liu P, Young AN, et al. Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene. 2005;24:188–198.
   PubMed Web of Science ®Google Scholar
• Ibeawuchi C, Schmidt H, Voss R, et al. Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy. IJMS. 2015;16:3856–3869.
   Web of Science ®Google Scholar
• Ronnau CG, Verhaegh GW, Luna-Velez MV, et al. Noncoding RNAs as novel biomarkers in prostate cancer. Biomed Res Int. 2014;2014:591703.
   PubMed Web of Science ®Google Scholar
• Niu WB, Gui SL, Lin YL, et al. Promoter methylation of protocadherin8 is an independent prognostic factor for biochemical recurrence of early-stage prostate cancer. Med Sci Monit. 2014;20:2584–2589.
   PubMed Web of Science ®Google Scholar
• Roberts MJ, Chow CW, Schirra HJ, et al. Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer. Prostate. 2015;75:539–549.
   PubMed Web of Science ®Google Scholar
• Henriquez-Hernandez LA, Valenciano A, Foro-Arnalot P, et al. Single nucleotide polymorphisms in DNA repair genes as risk factors associated to prostate cancer progression. BMC Med Genet. 2014;15:143.
   PubMed Web of Science ®Google Scholar
• Wang F, Ren S, Chen R, et al. Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer. Oncotarget. 2014;5:11091–11102.
   PubMedGoogle Scholar
• Li J, Wang Z, Chong T, et al. Over-expression of a poor prognostic marker in prostate cancer: AQP5 promotes cells growth and local invasion. World J Surg Onc. 2014;12:284.
   PubMed Web of Science ®Google Scholar
• Tait DL, Bahrani-Mostafavi Z, Vestal CG, et al. Downregulation of HOXC6 in serous ovarian cancer. Cancer Invest. 2015;33:303–311.
   PubMed Web of Science ®Google Scholar
• Vinarskaja A, Yamanaka M, Ingenwerth M, et al. DNA methylation and the HOXC6 paradox in prostate cancer. Cancers (Basel). 2011;3:3714–3725.
   PubMedGoogle Scholar
• Larsen BM, Hrycaj SM, Newman M, et al. Mesenchymal Hox6 function is required for mouse pancreatic endocrine cell differentiation. Development. 2015;142:3859–3868.
   PubMed Web of Science ®Google Scholar
• Du YB, Dong B, Shen LY, et al. The survival predictive significance of HOXC6 and HOXC8 in esophageal squamous cell carcinoma. J Surg Res. 2014;188:442–450.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Jin XS, Yang ZY, et al. Upregulated Hoxc6 expression is associated with poor survival in gastric cancer patients. Neoplasma. 2013;60:439–445.
   PubMed Web of Science ®Google Scholar